SecBot SecBot

DYN

Dyne Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001818794 Biotech & Drug Discovery
$16.70 −0.46 (−2.68%)
Nov 16 4:00 PM ET · prev $17.16
Market cap
$3.2B
Mid cap
Consensus
Buy
86% Buy or better · 21 analysts
Median target
$36.00
+116% · range $10.00–50.00
1 year
−17.5%
from $20.24 · Nov 17
30 days
+9.7%
from $15.23
52-week range
$14.25–26.78
−38% from high · low Oct 16
Avg volume 20D
2.41M
shares / day
Short interest
24.38M
≈13.0% of shares · −4.3%
Days to cover
10.8
at average volume
Insider net
−$112.0M
1 buyer · 6 sellers · since Jun 22
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
46
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 8 neutral oldest → newest, height = score
Avg score ·High conf. 7/10 ·Next FDA decision date, Jan 21, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $40.0K at an average $16.00. 6 insiders sold $112.1M.

  • InstitutionsMIXED

    Q2 2026: 19 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    18 of 21 rate it Buy or better. Median target $36.00 (+116%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.871 → −$1.023 over 90 days. 1 up, 4 down in 30 days.

  • Short sellersSTEADY

    Short interest −4.3% to 24.38M shares. 10.8 days to cover, ≈13.0% of shares.

  • TrendRANGE

    1% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCADD11,207,000$248.9M
PRICE T ROWE ASSOCIATES INC /MD/ADD3,936,806$87.4M
BANK OF AMERICA CORP /DE/ADD2,233,398$49.6M
GOLDMAN SACHS GROUP INCADD2,157,195$47.9M
DIMENSIONAL FUND ADVISORS LPDOUBLED1,946,479$43.2M
MARSHALL WACE, LLPDOUBLED1,488,917$33.1M
CITADEL ADVISORS LLCDOUBLED1,143,958$25.4M
Fiera Capital CorpTRIM789,989$17.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 86% rate it Buy or better
Strong Buy6Buy12Hold2Sell1Strong Sell0
12-month targets · 15 analysts

Price is inside the target range. Median implies +116%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 28, 2026Oppenheimer
DOWNGRADE
DOWNGRADEPerform
Sep 30, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 30, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 29, 2026Piper Sandler
REITERATE
REITERATEOverweight
Sep 9, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Sep 9, 2026JP Morgan
DOWNGRADE
DOWNGRADEUnderweight

Insider ledger

Form 4
$40.0K
bought · 1 insider
$112.1M
sold · 6 insiders
+4.4%
vs their $16.00 cost
DateInsiderTypeValue
Oct 20, 2026
Kerr Douglas
Head of R&D and CMO
Oct 20, 2026
AWARD12,000 sh
Oct 20, 2026
Kerr Douglas
Head of R&D and CMO
Oct 20, 2026
AWARD8,000 sh
Oct 2, 2026
Posner Brian S
Director
Oct 2, 2026
BUY$40.0K
Sep 8, 2026
Cox John
CEO & President
Sep 8, 2026
SELL$106.8K
Sep 8, 2026
Kerr Douglas
Chief Medical Officer
Sep 8, 2026
SELL$24.4K
Sep 8, 2026
Friedl-Naderer Johanna
Chief Commercial Officer
Sep 8, 2026
SELL$3.5K
Sep 4, 2026
Kerr Douglas
Chief Medical Officer
Sep 4, 2026
SELL$91.2K
Sep 4, 2026
Friedl-Naderer Johanna
Chief Commercial Officer
Sep 4, 2026
SELL$21.9K

Earnings setup

Estimates
−$1.02
EPS estimate, this quarter
−18%
estimate change, 90 days
1↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.02-$1.12–-$0.85-14.8%$0.00
Next Q-$1.00-$1.08–-$0.91-19.2%$3.0M
Current FY-$3.91-$4.00–-$3.83-10.3%$0.00
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

3 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
24,376,615
shares short
-4.3%
vs prior settlement
10.8
days to cover
≈13.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Director Douglas Kerr filed a Form 144 notice of intent to sell 2,604 shares of Dyne Therapeutics common stock, with…
144 · Impact 2/10
Nov 13, 2026 SEC
John Cox, an officer of Dyne Therapeutics, filed a Form 144 notice of intent to sell 5,513 shares of common stock…
144 · Impact 2/10
Nov 11, 2026 Other
Dyne Therapeutics to Participate in Upcoming Investor Conference
WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical
Oct 22, 2026 Press
Dyne Therapeutics granted inducement equity awards to 16 new hires, consisting of options for 290,100 shares and RSUs…
Impact 2/10
Oct 20, 2026 Insider
Kerr Douglas was granted 12,000 shares
Head of R&D and CMO
Oct 20, 2026 Insider
Kerr Douglas was granted 8,000 shares
Head of R&D and CMO
Oct 2, 2026 Insider
Posner Brian S bought 2,500 shares
Director @ $16.00 ($40.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

46 filings · 8 press releases · 3 bullish · 8 bearish · 2 mixed · 33 neutral
All DYN filing & press-release reports (54)